- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04313868
GEN2 Directed Cancer Immunotherapy Trial (GEN2)
A Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GEN2 in Refractory Patients With Primary Hepatocellular Carcinoma or Tumors Metastatic to the Liver
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This clinical trial will be divided into two phases: Phase IA in which the dose, route, and schedule of the GEN2 administration is determined and Phase IB which is designed to explore the activity of GEN2 in patients of a defined or several defined tumor types and stages based on the Phase IA data of GEN2.
Phase IA is divided into three routes of administration: (a) Phase 1A.1 which explores peripheral IV infusion; (b) Phase IA.2 which investigates hepatic arterial infusion and (c) Phase IA.3 which examines intratumoral delivery.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jennifer Olive Arellano
- Phone Number: +63286571871
- Email: jenny.arellano@novotech-cro.com
Study Contact Backup
- Name: Karl Bean
- Phone Number: +1-626-768-5032
- Email: kabean@genvivoinc.com
Study Locations
-
-
-
Makati City, Philippines, 1229
- Makati Medical Center
-
Pasig City, Philippines
- The Medical City
-
Quezon City, Philippines, 1112
- St. Luke's Medical Center
-
Quezon City, Philippines, 1101
- National Kidney and Transplant Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of histologically documented, advanced stage, primary or metastatic adult solid tumor(2) in the liver that are refractory to standard therapy or for which no curative standard therapy exists.
- Evidence of radiographically measurable or evaluation disease on a baseline PET-CT scan.
- All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedures must have resolved to National Cancer Institute (NCI) Common Toxicity Criteria (CTC) (Version 4.03) Grade < 1.
- Patient must be legally considered an adult in the country in which they are participating in the study.
- Last dose of antineoplastic therapy, except for hormonal therapy, must be > 21 days. External beam radiotherapy must have been <25% bone marrow-containing skeleton.
- Patients may be Hepatitis B and C positive.
- Patients may have intracranial metastases of any number if they have been brain irradiated and stable for 6 weeks. Patients may be taking anti-seizure medicines but must not be on steroids. Last dose of steroids must be >7 days.
- Karnofsky performance status must be > or = 70
- Childs-Pugh Classification Score of 7 or less
- Life Expectancy of at least 3 months
- Patients must be able to travel to alternate medical center for PET/CT scans, if necessary.
- Meet the required baseline laboratory data
- Signed informed consent indicating that they are aware of the neoplastic nature of their disease and have been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks and discomforts.
- Willing and able to comply with scheduled visits, treatment plan, and laboratory tests.
Exclusion Criteria:
- Concurrent therapy with anticancer agent including any other investigational agent.
- Existing intracranial edema or CVA within 6 months of screening
- Pregnant or breast-feeding women. Female patients must agree to use effective contraception, must be surgically sterile or must be post-menopausal. Male patients must agree to use effective contraception or be surgically sterile. The definition of effective contraception will be based on the judgment of the Investigator or a designated associate. All at-risk female patients must have a negative pregnancy test within 7 days prior to start of the study treatment.
- Clinically significant cardiac disease (New York Heart Associate, Class III or IV)
- Dementia or altered mental status that would prohibit informed consent.
- Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study.
- Known side effects to antivirals in the ganciclovir class
- Patients who are known to be HIV positive.
- Patients must not be taking steroids at the time of screening. Last dose of steroids must be >7 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1A.1: Peripheral IV
GEN2 is administered in repeating three week cycles.
On week one, GEN2 is given intravenously on three consecutive days and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days.
Valganciclovir dosing is initiated on day 7 to 9 for 5 days.
An approximately one week drug holiday follows.
|
GEN2 is an investigational drug combining cytotoxic and immunotherapy.
|
Experimental: Phase IA.2: Hepatic Artery Infusion
GEN2 is administered in repeating three week cycles.
On week one, GEN2 is given as a single hepatic artery infusion (HAI) on two successive days and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days.
Valganciclovir dosing is initiated on day 7 to 9 for 5 days.
An approximately one week drug holiday follows.
|
GEN2 is an investigational drug combining cytotoxic and immunotherapy.
|
Experimental: Phase IA.3: Intratumoral Injection
GEN2 is administered in repeating three week cycles.
On week one, GEN2 is given via injection directly into the tumor lesions on one day and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days.
Valganciclovir dosing is initiated on day 7 to 9 for 5 days.
An approximately one week drug holiday follows.
|
GEN2 is an investigational drug combining cytotoxic and immunotherapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: First 3 weeks of GEN2 Administration
|
The MTD is the defined as the highest dose level at which, at most, one patient experiences a DLT.
|
First 3 weeks of GEN2 Administration
|
Dose Limiting Toxicity (DLT)
Time Frame: First 3 weeks of GEN2 Administration
|
|
First 3 weeks of GEN2 Administration
|
Recommended Phase 2 Dose (RP2D)
Time Frame: First 3 weeks of GEN2 Administration
|
The RP2D will be administered for Phase 1B.
It is determined when the accelerated phase ends for Phase IA and the dose assignment for a new patient in the standard dose escalation will follow a modified Fibonacci scheme.
If a modified Fibonacci has already been used, the RP2D will be explored from the remaining intervals between the dose which had no DLTs and the Maximum Administered Dose (MAD).
|
First 3 weeks of GEN2 Administration
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: Treatment Initiation until 30 days after last dose of GEN2
|
Each Adverse Event is to be classified by the Investigator as serious or non-serious.
The classification of the gravity of the event determines the reporting procedures to be followed.
|
Treatment Initiation until 30 days after last dose of GEN2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma pharmacokinetics of GEN2
Time Frame: During Week 1 of Cycle 1, Cycle 2 & Cycle 6 (each cycle is 28 days)
|
GEN2 PK Cmax is dose proportional.
|
During Week 1 of Cycle 1, Cycle 2 & Cycle 6 (each cycle is 28 days)
|
HSV-TK-m2 protein expression from GEN2 via serial [18F]FHBG PET and/or SPECT imaging
Time Frame: Day 3-8 of GEN2 Treatment
|
Identify number of participants with positive [18F] FHBG scan
|
Day 3-8 of GEN2 Treatment
|
Preliminary Evidence of anti-tumor activity of GEN2
Time Frame: Week 9 and every 6 weeks thereafter through study completion, an average of 8 months.
|
Measure of anti-tumor efficacy based on objective tumor assessments made according to the irRECIST 1.1
|
Week 9 and every 6 weeks thereafter through study completion, an average of 8 months.
|
Clinical research testing for antibodies to retrovector gp70 env, replication-competent retrovirus in peripheral blood lymphocytes (PBLs); vector integration into genomic DNA of PBLs, and circulating hGM-CSF protein
Time Frame: Cycle 1, Cycle 2, Cycle 6, after 6th month on treatment, annually thereafter
|
No replication-competent retrovirus.
No vector integration into genomic DNA of PBLS.
No GM-CSF detectable in patients after GEN2 administration
|
Cycle 1, Cycle 2, Cycle 6, after 6th month on treatment, annually thereafter
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Priscilla B Caguioa, MD, St. Luke's Medical Center - Quezon City
- Principal Investigator: Maria Belen E Tamayo, MD, Makati Medical Center
- Principal Investigator: John P Querol, MD, The Medical City
- Principal Investigator: Necy S Juat, MD, National Kidney and Transplant Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPB-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
Clinical Trials on GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
-
The Methodist Hospital Research InstituteRecruitingProstate Cancer | High-risk Prostate CancerUnited States
-
Peking University Cancer Hospital & InstituteNot yet recruiting